Human MET peptide

Background: Immunotherapy is a new and promising approach to treating pediatric cancers. These types of therapies have unique mechanisms of action for identifying and fighting cancer, as compared with traditional chemotherapy, and therefore are associated with different therapy-related adverse events (AEs). The purpose of this systematic review was to review available evidence to: (a) identify commonly reported AEs associated with immunotherapy agents frequently used in pediatric oncology and (b) generate recommendations for nursing practice. Method: A clinical question was developed and used to guide the systematic literature review. Five immunotherapy agents (dinutuximab, blinatumomab, rituximab, inotuzumab ozogamicin, brentuximab vedotin) were selected for inclusion secondary to their high relevance to pediatric oncology. A literature search was conducted to locate articles published between January 1, 2003 and October 31, 2018. Results: Seventeen articles met eligibility criteria for inclusion and were evaluated using the Grading of Recommendations Assessment, Development, and Evaluation criteria. The most commonly reported AEs for the selected immunotherapy agents were identified and summarized. Strong recommendations are made for nurses to become familiar with the unique AE profiles associated with individual immunotherapy agents. Agent-specific recommendations for nursing practice regarding AEs associated with dinutuximab and rituximab were generated. Conclusions: Immunotherapy is rapidly emerging as an effective therapy for pediatric cancers. Nurses need to be aware of the breadth of agent-specific, immunotherapy-related AEs to appropriately monitor and manage patients receiving these therapies. Additional work is needed to confidently profile immunotherapy-related AEs in pediatric oncology and to develop agent-specific educational materials for patients/families.

Animal welfare assurance is of great importance as dairy farming is recently under increasing pressure to meet societal and commercial expectations. Therefore, this study aims to determine the current welfare situation of dairy cattle housed in tie-stalls and free stalls in South Tyrol (Eastern Italian Alps) in order to evaluate the need for establishment of an animal welfare assurance programme. For reasons of research economy, a protocol was used for data collection that would also be applicable for practical use in an animal welfare assurance scheme. Analyses of resource-based and animal-based indicators recorded in 204 farms in North and South Tyrol (1891 dairy cows) reveal some important animal welfare problems mainly related to the provision of resources and the prevalence of skin alterations especially in tie-stall barns, which are still widely spread in mountain areas. Hence, the implementation of an animal welfare assurance scheme is urgently needed to reflect public concerns through regular and standardised monitoring of welfare indicators and continuous encouragement of improvements in dairy cattle welfare towards predefined targets. Concerning tie-stalls, interventions in stall design as well as the selective use of local breeds best adapted to the mountainous conditions appear to be appropriate measures to optimise dairy cattle health and welfare. These findings substantiate the high value of the data that would be collected as part of the assurance programme to gain insights, which could be used in preventive and corrective health plans to improve welfare-friendliness in dairy farming of South Tyrol.